Skip to main content

Advertisement

SpringerLink
Log in

Cost-Benefit Analysis of a Haemophilus Influenzae Type B Meningitis Prevention Programme in The Philippines

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Background: Haemophilus influenzae type b (Hib) meningitis is associated with high mortality and serious sequelae in children under 5 years of age. Vaccines which can prevent this infection are available.

Objective: To evaluate the costs and benefits of a 3-dose immunisation schedule in Manila, Philippines.

Perspective: Government and societal perspectives.

Design and participants: A cost-benefit analysis based on a birth cohort of 100 000 children. The state of health of the cohort with and without a Hib immunisation programme was modelled over a 5-year period. A survey of medical records of patients with Hib in Manila provided data on the extent and cost of sequelae following infection. Intervention: A 3-dose Hib vaccination programme given at ages 2, 3 and 4 months.

Results: The model predicted that vaccinating children against Hib meningitis would prevent 553 cases per year in a birth cohort of 100 000, at a cost of 56 200 Philippine pesos (PHP) [$US1605; 1998 exchange rate] per case (base case assumptions of 90% vaccine efficacy rate, 95 per 100 000 Hib incidence rate, 85% vaccination coverage). Results from the cost-benefit analyses indicated that the saving to the government would be around PHP39 million ($US1.11 million), and the saving to society would be PHP255 million ($US7.28 million).

Conclusion: There would be a positive economic benefit for the Philippine government and for the Filipino society if a Hib vaccination programme was introduced in Manila.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

References

  1. Limcangco MR, Salole EG, Armour CL. Epidemiology of Haemophilus influenzae type bmeningitis in Manila, Philippines, 1994 to 1996. Pediatr Infect Dis J 2000; 19 (1): 7–11

    Article  PubMed  CAS  Google Scholar 

  2. Ferreccio C, Ortiz E, Astroza L, et al. A population-based retrospective assessment of the disease burden resulting from invasive Haemophilus influenzae in infants and young children in Santiago, Chile. Pediatr Infect Dis J 1990; 9 (7): 488–94

    Article  PubMed  CAS  Google Scholar 

  3. Bijlmer HA, van Alphen L, Greenwood BM, et al. The epidemiology of Haemophilus influenzae meningitis in children under five years of age in The Gambia, West Africa. J Infect Dis 1990; 161 (6): 1210–5

    Article  PubMed  CAS  Google Scholar 

  4. Gilsdorf JR. Bacterial meningitis in southwestern Alaska. Am J Epidemiol 1977; 106 (5): 388–91

    PubMed  CAS  Google Scholar 

  5. Trollfors B, Claesson BA, Strangert K, et al. Haemophilus influenzae meningitis in Sweden 1981–1983. Arch Dis Child 1987; 62 (12): 1220–5

    Article  PubMed  CAS  Google Scholar 

  6. Tudor-Williams G, Frankland J, Isaac D, et al. Haemophilus influenzae type b conjugate vaccine trial in Oxford: implications for the United Kingdom. Arch Dis Child 1989; 64 (4): 520–4

    Article  PubMed  CAS  Google Scholar 

  7. Takala AK, Eskola J, Peltola H, et al. Epidemiology of invasive Haemophilus influenzae type b disease among children in Finland before vaccination with Haemophilus influenzae conjugate vaccine. Pediatr Infect Dis J 1989; 8 (5): 297–302

    PubMed  CAS  Google Scholar 

  8. Hammond GW, Rutherford BE, Malazdrewicz R, et al. Haemophilus influenzae meningitis in Manitoba and the Keewatin District, NWT: potential for mass vaccination. CMAJ 1988; 139 (8): 743–7

    PubMed  CAS  Google Scholar 

  9. Gilbert GL, Johnson PD, Clements DA. Clinical manifestations and outcome of Haemophilus influenzae type b disease. J Paediatr Child Health 1995; 31 (2): 99–104

    Article  PubMed  CAS  Google Scholar 

  10. Thomas DG. Outcome of paediatric bacterial meningitis 1979- 1989. Med J Aust 1992; 157 (8): 519–20

    PubMed  CAS  Google Scholar 

  11. Campbell H, Carter H. Rational use of Haemophilus influenzae type b vaccine. Drugs 1993; 46 (3): 378–83

    Article  PubMed  CAS  Google Scholar 

  12. Hay JW, Daum RS. Cost-benefit analysis of Haemophilus influenzae type b prevention: conjugate vaccination at eighteen months of age. Pediatr Infect Dis J 1990; 9 (4): 246–52

    Article  PubMed  CAS  Google Scholar 

  13. Ginsberg GM, Kassis I, Dagan R. Cost benefit analysis of Haemophilus influenzae type b vaccination programme in Israel. J Epidemiol Community Health 1993; 47 (6): 485–90

    Article  PubMed  CAS  Google Scholar 

  14. Harris A, Hendrie D, Bowen C, et al. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP. Med J Aust 1994; 160 (8): 483–8

    PubMed  CAS  Google Scholar 

  15. Trollfors B. Cost-benefit analysis of general vaccination against Haemophilus influenzae type b in Sweden. Scand J Infect Dis 1994; 26 (5): 611–4

    Article  PubMed  CAS  Google Scholar 

  16. McIntyre P, Hall J, Leeder S. An economic analysis of alternatives for childhood immunisation against Haemophilus influenzae type b disease. Aust J Public Health 1994; 18 (4): 394–400

    Article  PubMed  CAS  Google Scholar 

  17. Hussey G, Hitchcock J, Shaaf H, et al. Epidemiology of invasive Haemophilus influenzae infections in Cape Town, South Africa. Ann Trop Paediatr 1994; 14: 97–103

    PubMed  CAS  Google Scholar 

  18. Levine OS, Ortiz E, Contreras R, et al. Cost-benefit analysis for the use of Haemophilus influenzae type b conjugate vaccine in Santiago, Chile. Am J Epidemiol 1993; 137 (11): 1221–8

    PubMed  CAS  Google Scholar 

  19. Midani S, Ayoub EM, Rathore MH. Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine program in Florida. J Fla Med Assoc 1995; 82 (6): 401–2

    PubMed  CAS  Google Scholar 

  20. Livartowski A, Boucher J, Detournay B, et al. Cost-effectiveness evaluation of vaccination against Haemophilus influenzae disease in France. Vaccine 1996; 14 (6): 495–500

    Article  PubMed  CAS  Google Scholar 

  21. Jimenez FJ, Guallar-Castillon P, Terres CR, et al. Cost-benefit analysis of Haemophilus influenzae type b vaccination in children in Spain. Pharmacoeconomics 1999; 15 (1): 75–83

    Article  PubMed  CAS  Google Scholar 

  22. Microsoft Corporation. Microsoft Excel version 5, 1996

  23. Shapiro ED, Capobianco LA, Berg AT, et al. The immunogenicity of Haemophilus influenzae type b polysaccharide-Neisseria meningitidis Group B outer membrane protein vaccine in infants and young children. J Infect Dis 1989; 160 (6): 1064–7

    Article  PubMed  CAS  Google Scholar 

  24. Watemberg N, Dagan R, Arbelli Y, et al. Safety and immunogenicity of Haemophilus type b-tetanus protein conjugate vaccine mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants. Pediatr Infect Dis J 1991; 10 (10): 758–63

    Article  PubMed  CAS  Google Scholar 

  25. Eskola J, Olander RM, Hovi T, et al. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996; 348: 1688–92

    Article  PubMed  CAS  Google Scholar 

  26. Capeding MR, Sombrero LT, Paladin FJ, et al. Etiology of acute respiratory infection in Filipino children under five years. South Asian J Trop Med Pub Health 1994; 25 (4): 684–7

    CAS  Google Scholar 

  27. National Economic Development Authority. 1996 economic performance. Manila: National Economic Development Authority, Republic of the Philippines, 1997

    Google Scholar 

  28. Drummond MF, O’Brien B, Stoddart GL, et al. Cost analysis. In: Methods for the economic evaluation of health care programmes. 2nd ed. New York (NY): Oxford University Press, 1997: 52–95

    Google Scholar 

  29. Rice DP, Hodgson TA, Kopstein AN. The economic cost of illness: a replication and update. Health Care Financ Rev 1985; 7 (1): 61–80

    PubMed  CAS  Google Scholar 

  30. Anonymous. Expanded Program on Immunization: immunization coverage in Metropolitan Manila. WHO Wkly Rec 1984; 63: 285–6

    Google Scholar 

  31. Department of Health (Republic of the Philippines). Field guide for National Immunization Day. Manila: UNICEF, 1994

    Google Scholar 

  32. Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991; 324 (25): 1767–72

    Article  PubMed  CAS  Google Scholar 

  33. Eskola J, Kayhty H, Takala AK, et al.A randomized, prospective field trial of conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990; 323 (20): 1381–7

    Article  PubMed  CAS  Google Scholar 

  34. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis with conjugate vaccines. Lancet 1992; 340: 592–4

    Article  PubMed  CAS  Google Scholar 

  35. Barbour ML, Booy R, Crook DWM, et al. Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine. Pediatr Infect Dis J 1993; 12 (6): 478–84

    Article  PubMed  CAS  Google Scholar 

  36. Starr J, Rogers T, Impallomeni M. Hospital-acquired Clostridium difficile diarrhoea and herd immunity. Lancet 1997; 349: 426–8

    Article  PubMed  CAS  Google Scholar 

  37. Takala AK, Eskola J, Leinonen M, et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunised with a Hib conjugate vaccine. J Infect Dis 1991; 164 (5): 982–6

    Article  PubMed  CAS  Google Scholar 

  38. Decker MD, Edwards KM, Bradley R, et al. Comparative trial in infants to four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992; 120 (2 Pt 1): 184–9

    Article  PubMed  CAS  Google Scholar 

  39. Ferreccio C, Clemens J, Avendano A, et al. The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheriatetanus toxoid-pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J 1991; 10 (10): 764–71

    Article  PubMed  CAS  Google Scholar 

  40. Capeding MR, Nohynek H, Pascual LG, et al. The immunogenicity of three Haemophilus influenzae type b conjugate vaccines after a primary vaccination series in Philippine infants. Am J Trop Med Hyg 1996; 55 (5): 516–20

    PubMed  CAS  Google Scholar 

  41. Lagos R, Horwitz I, Toro G, et al. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J 1996; 15 (3): 216–22

    Article  PubMed  CAS  Google Scholar 

  42. Booy R, Heath PT, Slack MPE, et al. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster. Lancet 1997; 349: 1197–202

    Article  PubMed  CAS  Google Scholar 

  43. Drummond MF, O’Brian B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. New York (NY): Oxford University Press, 1997

    Google Scholar 

  44. Solon O, Gamboa RM, Schwartz JB, et al. Health sector financing in the Philippines. Manila: Department of Health, 1992

    Google Scholar 

  45. Hay JW, Daum RS. Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection. Pediatrics 1987; 80 (3): 319–29

    PubMed  CAS  Google Scholar 

  46. Daum RS, Granoff DM. Lessons from evaluation of immunogenicity. In: Ellis R, Granoff DM, editor. Development and clinical use of Haemophilus influenzae b conjugate vaccines. New York (NY): Marcel Dekker Inc., 1994: 291

    Google Scholar 

  47. Tupasi TE, Lucero MG, Magdangal DM, et al. Etiology of acute lower respiratory tract infection in children from Alabang, Metro Manila. Rev Infect Dis 1990; 12 Suppl. 8: S929–39

    Article  Google Scholar 

  48. Tupasi TE, de Leon L, Lupisan S, et al. Community-based studies of acute respiratory tract infections in young children. Rev Infect Dis 1990; 12: S940-S949

    Article  Google Scholar 

  49. Department of Health (Republic of the Philippines). 1996 Operational Plan, Expanded Program on Immunization. Manila: Department of Health, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, College of Pharmacy, University of the Philippines — Manila, Manila, Philippines

    M. Rhona M. T. Limcangco

  2. School of Pharmacy, University of Sydney, New South Wales, Australia

    Carol L. Armour, Eugene G. Salole & Susan J. Taylor

Authors
  1. M. Rhona M. T. Limcangco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carol L. Armour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eugene G. Salole
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Susan J. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Rhona M. T. Limcangco.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Limcangco, M.R.M.T., Armour, C.L., Salole, E.G. et al. Cost-Benefit Analysis of a Haemophilus Influenzae Type B Meningitis Prevention Programme in The Philippines. Pharmacoeconomics 19, 391–400 (2001). https://doi.org/10.2165/00019053-200119040-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200119040-00006

Keywords

Search

Navigation